局部晚期直肠癌的全新辅助治疗：PRODIGE 23试验 - Suppr

Suppr

超能文献

Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: PRODIGE 23 Trial.

作者信息

Weiser Martin R

机构信息

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.

出版信息

Ann Surg Oncol. 2022 Mar;29(3):1493-1495. doi: 10.1245/s10434-021-11104-9. Epub 2021 Nov 26.

DOI:10.1245/s10434-021-11104-9

PMID:34837136

Abstract

摘要

相似文献

Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: PRODIGE 23 Trial.局部晚期直肠癌的全新辅助治疗：PRODIGE 23试验

Ann Surg Oncol. 2022 Mar;29(3):1493-1495. doi: 10.1245/s10434-021-11104-9. Epub 2021 Nov 26.

Stromal Organization as a Predictive Biomarker of Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer.基质组织作为局部晚期直肠癌新辅助治疗反应的预测生物标志物

J Gastrointest Surg. 2021 Aug;25(8):2116-2118. doi: 10.1007/s11605-021-04920-7. Epub 2021 Feb 5.

Chemoradiotherapy in Locally Advanced Rectal Cancer: Surgeon Perspective.局部晚期直肠癌的放化疗：外科医生视角

J Clin Oncol. 2022 Dec 1;40(34):4029. doi: 10.1200/JCO.22.00934. Epub 2022 Aug 5.

Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial.直肠癌新辅助放化疗及保守治疗后的临床完全缓解（cCR）。ACCORD 12/PRODIGE 2随机试验结果

Radiother Oncol. 2015 May;115(2):246-52. doi: 10.1016/j.radonc.2015.04.003. Epub 2015 Apr 24.

Tailored total neoadjuvant therapy for locally advanced rectal cancer: One size may not fit for all!个体化新辅助治疗局部进展期直肠癌：一种方法并不适合所有人！

Colorectal Dis. 2021 Jul;23(7):1662-1669. doi: 10.1111/codi.15669. Epub 2021 Apr 22.

[The value of MR T2WI signal intensity related parameters for predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer].[磁共振T2WI信号强度相关参数对预测局部晚期直肠癌新辅助放化疗病理完全缓解的价值]

Zhonghua Zhong Liu Za Zhi. 2019 Nov 23;41(11):837-843. doi: 10.3760/cma.j.issn.0253-3766.2019.11.007.

Oncologic and survival outcomes in elderly patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy and total mesorectal excision.接受新辅助放化疗及全直肠系膜切除术的老年局部晚期直肠癌患者的肿瘤学及生存结局

Jpn J Clin Oncol. 2021 Aug 30;51(9):1391-1399. doi: 10.1093/jjco/hyab095.

[Neoadjuvant treatment for rectal cancer].[直肠癌的新辅助治疗]

Bull Cancer. 2021 Sep;108(9):855-867. doi: 10.1016/j.bulcan.2021.03.018. Epub 2021 Jun 14.

Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).韩国结直肠外科学会（KSCP）新辅助同期放化疗后局部中低位进展期直肠癌巩固化疗的临床试验：一项多中心、随机对照试验（KONCLUDE）。

BMC Cancer. 2018 May 8;18(1):538. doi: 10.1186/s12885-018-4466-7.

The role of tissue diagnosis prior to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.组织诊断在局部晚期直肠癌新辅助放化疗前的作用。

Colorectal Dis. 2014 Oct;16(10):783-7. doi: 10.1111/codi.12653.

引用本文的文献

Total neoadjuvant therapy for locally advanced rectal cancer.局部晚期直肠癌的全新辅助治疗

Cochrane Database Syst Rev. 2025 May 14;5(5):CD015590. doi: 10.1002/14651858.CD015590.

The impact of short-course total neoadjuvant therapy, long-course chemoradiotherapy, and upfront surgery on the technical difficulty of total mesorectal excision: an observational study with an intraoperative perspective.短程全新辅助治疗、长程放化疗及 upfront 手术对全直肠系膜切除技术难度的影响：一项术中视角的观察性研究

Ann Coloproctol. 2024 Oct;40(5):451-458. doi: 10.3393/ac.2023.00899.0128. Epub 2024 Sep 19.

Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy.错配修复系统蛋白缺陷作为接受新辅助放化疗的局部晚期直肠腺癌患者的耐药因素。

Br J Cancer. 2023 Nov;129(10):1619-1624. doi: 10.1038/s41416-023-02444-2. Epub 2023 Sep 25.

MicroRNA-19b Plays a Key Role in 5-Fluorouracil Resistance and Predicts Tumor Progression in Locally Advanced Rectal Cancer Patients.MicroRNA-19b 在 5-氟尿嘧啶耐药中发挥关键作用，并可预测局部晚期直肠癌患者的肿瘤进展。

Int J Mol Sci. 2022 Oct 18;23(20):12447. doi: 10.3390/ijms232012447.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验